AFT PHARMACEUTICALS LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.09 NZD | +0.65% |
|
-1.59% | -11.71% |
Valuation
| Fiscal Period: März | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 194.6 | 353.2 | 517.7 | 378 | 362.8 | 324 | - | - |
| Enterprise Value (EV) 1 | 229.5 | 394.3 | 552.8 | 407.3 | 392.7 | 352.3 | 350.9 | 349.1 |
| P/E ratio | -66.7 x | 30.3 x | 70.7 x | 19 x | 34.6 x | 21.3 x | 18.7 x | 13.7 x |
| Yield | - | - | - | - | - | 0.52% | 0.74% | 1.46% |
| Capitalization / Revenue | 2.29 x | 3.35 x | 4.58 x | 2.9 x | 2.32 x | 1.68 x | 1.47 x | 1.26 x |
| EV / Revenue | 2.7 x | 3.73 x | 4.89 x | 3.13 x | 2.51 x | 1.83 x | 1.59 x | 1.36 x |
| EV / EBITDA | 35.7 x | 31.5 x | 46.8 x | 19 x | 18.4 x | 13.5 x | 12.1 x | 9.21 x |
| EV / FCF | - | - | -101 x | 47.5 x | 160 x | 44.7 x | 44.2 x | 14.9 x |
| FCF Yield | - | - | -0.99% | 2.1% | 0.62% | 2.24% | 2.26% | 6.69% |
| Price to Book | 38.5 x | 20.5 x | 14.2 x | 6.66 x | 4.95 x | 5.3 x | 4.49 x | 3.63 x |
| Nbr of stocks (in thousands) | 97,308 | 97,309 | 104,584 | 104,697 | 104,866 | 104,866 | - | - |
| Reference price 2 | 2.000 | 3.630 | 4.950 | 3.610 | 3.460 | 3.090 | 3.090 | 3.090 |
| Announcement Date | 5/21/19 | 5/19/20 | 5/23/21 | 5/22/22 | 5/22/23 | - | - | - |
1NZD in Million2NZD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: März | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 85.13 | 105.6 | 113.1 | 130.3 | 156.6 | 192.6 | 220.2 | 257.3 |
| EBITDA 1 | 6.435 | 12.52 | 11.81 | 21.43 | 21.39 | 26.01 | 29.04 | 37.91 |
| EBIT 1 | 6.116 | 11.42 | 10.71 | 20.39 | 19.67 | 23.94 | 26.85 | 40.53 |
| Operating Margin | 7.18% | 10.82% | 9.47% | 15.65% | 12.56% | 12.43% | 12.19% | 15.75% |
| Earnings before Tax (EBT) 1 | -2.259 | 12.88 | 7.887 | 18.68 | 15.8 | 21.09 | 23.53 | 28.39 |
| Net income 1 | -2.427 | 12.7 | 7.8 | 19.85 | 10.65 | 15.14 | 17.17 | 23.69 |
| Net margin | -2.85% | 12.03% | 6.9% | 15.23% | 6.8% | 7.86% | 7.8% | 9.2% |
| EPS 2 | -0.0300 | 0.1200 | 0.0700 | 0.1900 | 0.1000 | 0.1451 | 0.1654 | 0.2259 |
| Free Cash Flow 1 | - | - | -5.481 | 8.567 | 2.452 | 7.886 | 7.942 | 23.36 |
| FCF margin | - | - | -4.85% | 6.57% | 1.57% | 4.1% | 3.61% | 9.08% |
| FCF Conversion (EBITDA) | - | - | - | 39.97% | 11.46% | 30.32% | 27.35% | 61.62% |
| FCF Conversion (Net income) | - | - | - | 43.16% | 23.01% | 52.08% | 46.24% | 98.64% |
| Dividend per Share 2 | - | - | - | - | - | 0.0162 | 0.0227 | 0.0450 |
| Announcement Date | 5/21/19 | 5/19/20 | 5/23/21 | 5/22/22 | 5/22/23 | - | - | - |
1NZD in Million2NZD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 48.82 | 64.28 | 55.51 | 74.8 | - | - | 83.61 | 110.6 |
| EBITDA 1 | 2.985 | - | - | - | - | - | 4.098 | 21.9 |
| EBIT 1 | 2.422 | 8.286 | 5.491 | 14.9 | 3.457 | 16.21 | 3.25 | 20.8 |
| Operating Margin | 4.96% | 12.89% | 9.89% | 19.92% | - | - | 3.89% | 18.81% |
| Earnings before Tax (EBT) 1 | - | - | - | - | - | - | 1.968 | 18.7 |
| Net income 1 | 1.192 | 6.61 | 4.182 | 15.67 | 1.452 | 9.202 | 1.816 | 13.1 |
| Net margin | 2.44% | 10.28% | 7.53% | 20.94% | - | - | 2.17% | 11.84% |
| EPS | 0.0100 | 0.0600 | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 11/18/20 | 5/23/21 | 11/17/21 | 5/22/22 | 11/23/22 | 5/22/23 | 11/22/23 | - |
1NZD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 34.8 | 41.1 | 35.2 | 29.3 | 29.9 | 28.3 | 26.9 | 25.1 |
| Net Cash position 1 | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 5.413 x | 3.281 x | 2.976 x | 1.367 x | 1.398 x | 1.087 x | 0.9255 x | 0.6614 x |
| Free Cash Flow 1 | - | - | -5.48 | 8.57 | 2.45 | 7.89 | 7.94 | 23.4 |
| ROE (net income / shareholders' equity) | -39% | 114% | 28.9% | 42.5% | 15.7% | 17.9% | 16.9% | 20% |
| ROA (Net income/ Total Assets) | - | - | 8.1% | 17.5% | 7.74% | 14.6% | 14.1% | 16.9% |
| Assets 1 | - | - | 96.31 | 113.4 | 137.7 | 103.8 | 121.6 | 140.1 |
| Book Value Per Share 2 | 0.0500 | 0.1800 | 0.3500 | 0.5400 | 0.7000 | 0.5800 | 0.6900 | 0.8500 |
| Cash Flow per Share 2 | - | - | 0.0100 | 0.1400 | 0.1100 | 0.1500 | 0.1500 | 0.2300 |
| Capex 1 | 3.47 | 6.56 | 6.23 | 5.59 | 9.18 | 8.94 | 9.46 | 10.4 |
| Capex / Sales | 4.07% | 6.21% | 5.51% | 4.29% | 5.86% | 4.64% | 4.3% | 4.04% |
| Announcement Date | 5/21/19 | 5/19/20 | 5/23/21 | 5/22/22 | 5/22/23 | - | - | - |
1NZD in Million2NZD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
3.09
NZD
Average target price
3.7
NZD
Spread / Average Target
+19.74%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -11.71% | 192M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- AFT Stock
- Financials AFT Pharmaceuticals Limited
